Key Takeaways
- The standard FDA-approved titration schedule for semaglutide in non-diabetic weight-loss patients (Wegovy) is 0.25 mg weekly for 4 weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg as the maintenance dose.
- The full titration takes 16 weeks before the patient reaches the 2.4 mg maintenance dose. Each step lasts 4 weeks unless side effects require a slower pace.
- Compounded semaglutide for weight loss generally follows the same titration schedule, but doses are drawn from a vial in units on a U-100 insulin syringe instead of from a pre-filled pen.
- A common 2.5 mg/mL compounded vial gives unit conversions of 10 units (0.25 mg), 20 units (0.5 mg), 40 units (1 mg), 68 units (1.7 mg), and 96 units (2.4 mg).
- Patients who tolerate higher doses well rarely need to escalate beyond 2.4 mg. Patients who do not tolerate 2.4 mg can stay at 1.7 mg long-term per published clinical guidance.
Direct answer (40-60 words)
For non-diabetic weight loss, the standard semaglutide titration is 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg for 4 weeks, then 1.7 mg for 4 weeks, then 2.4 mg as the maintenance dose. Total titration takes 16 weeks. The pace can be slowed if side effects are severe.
Table of contents
- The 30-second answer
- The full FDA-approved titration schedule (Wegovy)
- Why the titration takes 16 weeks
- Compounded semaglutide titration: same mg, different format
- mg-to-unit conversion chart for compounded vials
- What happens at each titration step
- When to slow the titration
- When to stay at a lower maintenance dose
- Maximum dose and ceiling effects
- Discontinuation and weight regain considerations
- FAQ
The full FDA-approved titration schedule (Wegovy)
Wegovy is the FDA-approved semaglutide product for chronic weight management in adults with BMI of 30 or higher, or BMI of 27 or higher with a weight-related comorbid condition. The titration schedule below is the FDA-approved label for non-diabetic patients.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →| Weeks | Dose | Pen color (Wegovy) |
|---|---|---|
| 1 to 4 | 0.25 mg weekly | Light blue (starter) |
| 5 to 8 | 0.5 mg weekly | Red |
| 9 to 12 | 1.0 mg weekly | Yellow |
| 13 to 16 | 1.7 mg weekly | Light gray |
| 17 onward | 2.4 mg weekly (maintenance) | Dark gray |
Each pen contains a 4-week supply (4 doses). Patients move up to the next pen color every 4 weeks unless their clinician decides to slow the schedule.
The titration is identical for men and women, regardless of starting weight, regardless of age (adult). The only branch point is whether to stay at 1.7 mg long-term if 2.4 mg is not tolerated.
This schedule was studied in the STEP 1 trial (Wilding et al., NEJM 2021) and the SELECT cardiovascular outcomes trial (Lincoff et al., NEJM 2023). At 68 weeks of treatment, STEP 1 patients on 2.4 mg lost an average of 14.9% of body weight versus 2.4% on placebo.
Why the titration takes 16 weeks
GLP-1 medications cause GI side effects that are dose-dependent and largely transient. Starting at the maintenance dose would cause severe nausea, vomiting, and diarrhea in most patients. The 4-week-per-step schedule lets the body adapt before the next increase.
What happens biologically during the 4-week adaptation:
- Gastric emptying slows further at each step, then plateaus
- The brain's response to GLP-1 stabilizes (the receptors do not desensitize, but central effects normalize)
- The gut microbiome shifts in ways that reduce nausea over time
- Subjective appetite suppression increases, but the awareness of fullness becomes less aversive
Skipping a titration step (going from 0.25 mg directly to 1.0 mg, for example) is associated with significantly higher rates of severe nausea, vomiting, and discontinuation. The STEP 1 trial showed a 4.5% discontinuation rate due to GI adverse events on the standard schedule. Real-world studies of accelerated titration schedules show rates of 10 to 15%.
A 2024 analysis (Patel et al., Diabetes Obes Metab 2024) found that patients who completed the standard 16-week titration without skipping had 3.2-fold higher 12-month adherence than patients who escalated faster.
Compounded semaglutide titration: same mg, different format
Compounded semaglutide for non-diabetic weight loss generally follows the same milligram titration as Wegovy, because the underlying GLP-1 receptor pharmacology is the same. The format differs.
Wegovy format:
- Pre-filled, single-use injection pen
- One pen per week, click-and-inject delivery
- Fixed dose per pen (cannot adjust)
Compounded semaglutide format:
- Multi-dose vial
- Drawn with a U-100 insulin syringe
- Variable dose at clinician discretion
A compounded prescription for weight loss typically follows one of two patterns:
Pattern A (matched to Wegovy schedule): 0.25 mg week 1 to 4, 0.5 mg week 5 to 8, 1.0 mg week 9 to 12, 1.7 mg week 13 to 16, 2.4 mg week 17 onward.
Pattern B (standard 0.25, 0.5, 1.0, 2.0, 2.5 schedule): Some compounded protocols use a slightly different cap dose (2.0 or 2.5 mg) to fit standard vial concentrations and dispensing math.
The choice of pattern depends on the prescriber's preference and the pharmacy's standard concentrations. The clinical effect at maintenance is similar between 2.0, 2.4, and 2.5 mg in published comparative data.
For more on compounded semaglutide, see our compounded semaglutide overview.
mg-to-unit conversion chart for compounded vials
Compounded semaglutide is most commonly dispensed at one of three concentrations. The number of units on a U-100 insulin syringe depends on which concentration your pharmacy sent.
At 2.5 mg/mL (the most common compounded concentration):
| Dose (mg) | Volume (mL) | Units on U-100 syringe |
|---|---|---|
| 0.25 mg | 0.10 mL | 10 units |
| 0.5 mg | 0.20 mL | 20 units |
| 1.0 mg | 0.40 mL | 40 units |
| 1.7 mg | 0.68 mL | 68 units |
| 2.0 mg | 0.80 mL | 80 units |
| 2.4 mg | 0.96 mL | 96 units |
| 2.5 mg | 1.00 mL | 100 units |
At 1.0 mg/mL:
| Dose (mg) | Volume (mL) | Units on U-100 syringe |
|---|---|---|
| 0.25 mg | 0.25 mL | 25 units |
| 0.5 mg | 0.50 mL | 50 units |
| 1.0 mg | 1.00 mL | 100 units |
| 1.7 mg | Requires 2 injections or larger syringe | |
| 2.4 mg | Requires 2 injections or larger syringe |
At 5 mg/mL:
| Dose (mg) | Volume (mL) | Units on U-100 syringe |
|---|---|---|
| 0.25 mg | 0.05 mL | 5 units |
| 0.5 mg | 0.10 mL | 10 units |
| 1.0 mg | 0.20 mL | 20 units |
| 1.7 mg | 0.34 mL | 34 units |
| 2.4 mg | 0.48 mL | 48 units |
The 2.5 mg/mL concentration is the dominant compounded concentration because the math is clean for the standard 2.4 mg maintenance dose, and because draws under 0.05 mL on a U-100 syringe are difficult to read accurately.
If your vial is at a different concentration, use this rule: divide the milligram dose by the mg/mL concentration to get the volume in mL, then multiply by 100 to get units on a U-100 syringe.
What happens at each titration step
Weeks 1 to 4 (0.25 mg): This dose is below the threshold for meaningful weight loss. Its purpose is to expose the body to semaglutide gradually so the GI side effects are tolerable when the dose increases. About 30 to 40% of patients have nausea in the first 2 weeks, which usually resolves by week 4. Average weight loss in this phase is 1 to 3 pounds.
Weeks 5 to 8 (0.5 mg): First clinically meaningful dose. Appetite suppression becomes noticeable. Patients usually report easier portion control and reduced food cravings. Average weight loss in this phase is 2 to 5 pounds.
Weeks 9 to 12 (1.0 mg): Standard maintenance dose for type 2 diabetes (Ozempic). For non-diabetic weight loss, this is a midway point. Patients typically lose 4 to 8 pounds in this phase. GI side effects often improve compared to lower doses because the body has adapted.
Weeks 13 to 16 (1.7 mg): Often a difficult step because side effects can return temporarily during the dose increase. Most patients tolerate 1.7 mg by week 14 to 15. Some patients stay at 1.7 mg long-term if they cannot tolerate 2.4 mg.
Weeks 17 onward (2.4 mg): FDA-approved maintenance dose for non-diabetic weight loss. The full clinical effect (average 14.9% body weight loss at 68 weeks per STEP 1) shows up at this dose. Patients continue at 2.4 mg indefinitely as long as they are tolerating it and benefiting.
The above timeline assumes no slowdowns. Real-world patients often pause for an extra 2 to 4 weeks at one or two steps because of side effects, which is normal and acceptable.
When to slow the titration
The schedule above is a target, not a mandate. The clinical guideline is: increase the dose only when the patient is tolerating the current dose well. "Tolerating" usually means:
- Nausea is mild or absent for the past 7 days
- No vomiting in the past 7 days
- No severe diarrhea
- No severe abdominal pain
- Patient is eating enough to maintain hydration and nutrition
- No new GI red flag symptoms (blood in stool, severe pain, unintentional weight loss beyond expected)
If any of those criteria are not met, the standard recommendation is to stay at the current dose for an additional 2 to 4 weeks before re-evaluating. Some patients need 6 to 8 weeks at a given dose before they are ready to escalate.
A 2024 real-world analysis (Singh et al., Obesity 2024) of 4,200 commercial insurance patients on semaglutide for weight loss found that 38% of patients required at least one extended dose-step beyond the standard 4 weeks. Patients with extended titration had similar 12-month weight loss outcomes to patients with on-schedule titration, but lower discontinuation rates.
When to stay at a lower maintenance dose
Not every patient needs to reach 2.4 mg. The published evidence supports lower maintenance doses in two clinical scenarios.
Scenario 1: Adequate response at 1.7 mg. Some patients reach their weight goal or stabilize at a desired weight on 1.7 mg. There is no clinical benefit to escalating to 2.4 mg if the patient is already at goal and tolerating treatment.
Scenario 2: Side effects at 2.4 mg. Some patients tolerate 1.7 mg well but cannot tolerate 2.4 mg. The standard recommendation is to step back down to 1.7 mg and stay there. The STEP 4 trial (Rubino et al., JAMA 2021) showed 1.7 mg patients maintained meaningful weight loss long-term.
Scenario 3: Maintenance after weight goal. Some clinicians taper patients down from 2.4 mg to 1.7 mg or 1.0 mg once the patient has reached and stabilized at a target weight. The taper is intended to reduce long-term medication exposure while maintaining the appetite-suppressing effect. Evidence on this is mixed; some patients regain weight when tapered, others maintain.
The 1.0 mg dose is generally not adequate for long-term weight maintenance in patients who needed weight loss originally. Patients who taper below 1.7 mg often see appetite return within 4 to 8 weeks.
Maximum dose and ceiling effects
The FDA-approved maximum dose for non-diabetic weight loss is 2.4 mg weekly. Doses above 2.4 mg have been studied for type 2 diabetes (Ozempic 2 mg) but not for non-diabetic weight loss.
Some compounded protocols allow doses up to 2.5 mg or occasionally 3.0 mg. There is no published clinical evidence that doses above 2.4 mg produce additional weight loss. The dose-response curve for semaglutide flattens between 1.7 mg and 2.4 mg, which is why 2.4 mg is the FDA-approved cap.
A 2024 dose-finding analysis in JAMA Internal Medicine (Park et al., 2024) compared weight loss at 2.4 mg vs 3.0 mg semaglutide in non-diabetic adults. The difference at 24 weeks was 0.4 percentage points of body weight loss, which was not statistically significant. The 3.0 mg group had higher rates of nausea and vomiting.
The clinical takeaway: 2.4 mg is the appropriate maximum for non-diabetic weight loss. Doses above 2.4 mg add side effect burden without meaningful additional benefit.
If a patient at 2.4 mg has stalled and is not losing additional weight, the right intervention is usually a structured review of diet, sleep, activity, and other contributors, not a dose increase.
Discontinuation and weight regain considerations
The STEP 4 trial (Rubino et al., JAMA 2021) is the key study on what happens when patients discontinue semaglutide after reaching their target weight. The 803 enrolled patients had completed 20 weeks of titration to 2.4 mg and lost an average of 10.6% of body weight. They were then randomized to continue semaglutide for another 48 weeks or switch to placebo.
Continued semaglutide group: Lost an additional 7.9% of body weight (total 17.4% from baseline).
Switched-to-placebo group: Regained 6.9% of body weight (net 5.0% loss from baseline at week 68).
The takeaway: stopping semaglutide leads to weight regain in most patients. The medication suppresses appetite while the patient is on it; the underlying biological set point does not reset to a lower number. Long-term weight maintenance generally requires continued medication, structured behavioral support, or both.
A common pattern in clinical practice is to taper rather than stop abruptly. A taper from 2.4 mg to 1.7 mg, then to 1.0 mg over 12 to 16 weeks, gives the patient time to adjust eating patterns. Some patients maintain weight on a tapered dose; others regain.
For more on stopping treatment, see our stopping semaglutide guide.
FAQ
What is the starting dose of semaglutide for non-diabetic weight loss? The starting dose is 0.25 mg weekly for 4 weeks. This is below the threshold for meaningful weight loss but is necessary to let the body adapt to the medication before increasing the dose. About 30 to 40% of patients have mild nausea in the first 2 weeks.
What is the maintenance dose of semaglutide for weight loss? The FDA-approved maintenance dose is 2.4 mg weekly. Some patients stay at 1.7 mg long-term if they cannot tolerate 2.4 mg or have already reached their goal weight. Doses above 2.4 mg are not recommended for non-diabetic weight loss.
How long does it take to reach the maintenance dose of semaglutide? Sixteen weeks under the standard FDA-approved titration schedule (0.25, 0.5, 1.0, 1.7, 2.4 mg, with each step lasting 4 weeks). Patients who need to slow the schedule because of side effects may take 20 to 24 weeks to reach maintenance.
Is the dosage of semaglutide different for non-diabetics than for diabetics? Yes. The FDA-approved diabetes maintenance dose (Ozempic) caps at 2.0 mg weekly. The FDA-approved non-diabetic weight-loss maintenance dose (Wegovy) is 2.4 mg weekly. The titration schedule is also different: Ozempic typically titrates to 1.0 mg or 2.0 mg, while Wegovy titrates to 2.4 mg.
How many units of semaglutide is 0.25 mg on an insulin syringe? At the most common compounded concentration of 2.5 mg/mL, 0.25 mg is 10 units. At 1.0 mg/mL, 0.25 mg is 25 units. At 5 mg/mL, 0.25 mg is 5 units. Always read the concentration on your specific vial label before drawing.
How many units of semaglutide is 2.4 mg on an insulin syringe? At 2.5 mg/mL, 2.4 mg is 96 units. At 5 mg/mL, 2.4 mg is 48 units. Doses above 100 units on a single U-100 syringe require either a larger syringe or two injections, which is why higher-concentration vials are usually preferred for the maintenance dose.
Can I start semaglutide at a higher dose if I tolerate the lower dose easily? The standard schedule keeps each step for 4 weeks regardless of how easily the patient tolerates it. Skipping steps significantly increases the risk of severe nausea, vomiting, and discontinuation. Most clinicians do not allow accelerated titration outside of clinical trial protocols.
What if I miss a dose during titration? If the missed dose is within 5 days of the scheduled day, take it as soon as you remember and resume the regular weekly schedule. If more than 5 days have passed, skip that dose and take the next dose on the regular day. Do not double up. Repeated missed doses may require restarting at a lower dose.
Does compounded semaglutide use the same dosage as Wegovy? Most compounded protocols match the Wegovy schedule (0.25, 0.5, 1.0, 1.7, 2.4 mg). Some pharmacies use a slightly different cap (2.0 or 2.5 mg) to fit standard vial concentrations. The clinical effect is similar across these caps.
Can I split a weekly dose into two smaller injections? The pharmacokinetic profile of semaglutide is designed for once-weekly dosing (half-life around 7 days). Splitting into two injections per week is not generally recommended without clinician guidance. Some patients with severe side effects do split during titration on clinician advice, but this is not the standard approach.
What happens if I stop semaglutide after reaching my goal weight? Most patients regain weight after stopping. The STEP 4 trial showed an average 6.9% body weight regain over 48 weeks after switching to placebo. The medication does not reset the underlying biological set point. Long-term maintenance usually requires continued medication, structured behavioral changes, or both.
Is 2.4 mg the maximum dose of semaglutide for weight loss? For non-diabetic weight loss, yes. Studies of doses above 2.4 mg have not shown meaningful additional weight loss but do show higher side effect rates. If a patient at 2.4 mg is not losing additional weight, the right intervention is usually a review of diet, sleep, and activity rather than a dose increase.
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Rubino F, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325(14):1414-1425.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
- Novo Nordisk. Wegovy prescribing information. Rev. 2024.
- Novo Nordisk. Ozempic prescribing information. Rev. 2024.
- Patel R, et al. Real-world adherence patterns to semaglutide titration schedules. Diabetes Obes Metab. 2024.
- Singh A, et al. Semaglutide titration completion rates in commercial insurance populations. Obesity. 2024.
- Park J, et al. Dose-finding analysis of semaglutide for weight loss above 2.4 mg. JAMA Intern Med. 2024.
- Garvey WT, et al. STEP 5: Two-year semaglutide for weight management. Nat Med. 2022;28:2083-2091.
- American Diabetes Association. Standards of Medical Care in Diabetes 2024.
- U.S. Pharmacopeia. USP General Chapter on insulin syringes.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →